🧬 Gene & Cell Therapy: Key Highlights in Global Trials, Funding, and Regulatory Milestones 👁️❤️🧠
This week’s roundup brings you the most pivotal developments across the gene and cell therapy landscape—from clinical trial suspensions and billion-euro reimbursements to major funding rounds and early-phase successes in rare disease, ophthalmology, cardiology, and neurology.
🚨 Top Headlines You’ll Learn About:
⚠️ EMA suspends Sarepta’s Duchenne gene therapy trials after a patient death
🇩🇪 Germany greenlights performance-based reimbursement for Hemgenix in Hemophilia B
🔬 Bluebird Bio partners with Xcellbio to scale up Sickle Cell Disease therapy
💰 CIRM awards $8 million to Tr1X for GvHD regulatory T cell trial
🌍 GeneVentiv licenses a universal gene editing therapy for Pompe disease
🚀 FDA approves Minovia’s Pearson syndrome mitochondrial cell therapy trial
💸 Atsena raises $150 million to advance retinal gene therapies
👁️ Opus Genetics shows early success treating pediatric retinal disease
🧿 Alcon acquires Aurion Biotech to expand in eye cell therapy
💡 Neurona raises $102 million for Phase 3 epilepsy cell therapy trial
🦵 Pacira kicks off Phase 2 trial for knee osteoarthritis gene therapy
❤️ Lexeo’s heart-targeted gene therapy shows strong interim results in rare cardiomyopathy
📢 Stay Ahead in Gene and Cell Therapy Research!
✅ Like, share, and subscribe for weekly updates on rare diseases, regenerative medicine, and emerging gene therapies.
#GeneTherapy #CellTherapy #BiotechNews #SickleCell #HemophiliaB #PompeDisease #EpilepsyTreatment #Ophthalmology #Neurology #Duchenne #RetinalDisease #LucidQuest #MedicalInnovation #RareDiseaseResearch #ClinicalTrials